Braveheart Bio (BRVE) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $18.71, -4.30% vs the prior close of $19.55.
- Volume 414.85K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BRVE slides 4.3% to $18.71. Closed at $18.71, -4.30% vs the prior close of $19.55. Day range $18.01–$19.59, opened at $19.50.
BRVE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BRVE slides 4.3% to $18.71
- Closed at $18.71, -4.30% vs the prior close of $19.55. Day range $18.01–$19.59, opened at $19.50.
- Volume was 414.85K shares, 0.8x its 50-day average of 528.37K.
- Price is -24.4% vs its 50-day average ($24.74).
- 52-week range $17.86–$32.00; today's close sits at 6% of that range, 41.5% below the 52-week high.
Oct 15, 2026 — BRVE rises 1.1% to $19.55
- Closed at $19.55, +1.09% vs the prior close of $19.34. Day range $19.18–$20.13, opened at $19.54.
- Volume was 206.10K shares, 0.4x its 50-day average of 534.95K — lighter than usual.
- Price is -21.7% vs its 50-day average ($24.96).
- 52-week range $17.86–$32.00; today's close sits at 12% of that range, 38.9% below the 52-week high.
Oct 14, 2026 — BRVE ends flat (+0.1%) to $19.34
- Closed at $19.34, +0.05% vs the prior close of $19.33. Day range $18.62–$19.90, opened at $19.33.
- Volume was 462.80K shares, 0.9x its 50-day average of 536.45K.
- 52-week range $17.86–$32.00; today's close sits at 10% of that range, 39.6% below the 52-week high.
Oct 13, 2026 — BRVE slides 5.1% to $19.33
- Closed at $19.33, -5.06% vs the prior close of $20.36. Day range $19.04–$20.56, opened at $20.44.
- Volume was 212.30K shares, 0.4x its 50-day average of 543.35K — lighter than usual.
- 52-week range $17.86–$32.00; today's close sits at 10% of that range, 39.6% below the 52-week high.
Oct 12, 2026 — BRVE rises 1.7% to $20.36, 3 up days in a row
- Closed at $20.36, +1.70% vs the prior close of $20.02. Day range $19.22–$20.78, opened at $20.17.
- Volume was 155.10K shares, 0.3x its 50-day average of 551.79K — lighter than usual.
- 52-week range $17.86–$32.00; today's close sits at 18% of that range, 36.4% below the 52-week high.
- That makes 3 straight gains.
Oct 9, 2026 — BRVE jumps 4.9% to $20.02
- Closed at $20.02, +4.87% vs the prior close of $19.09. Day range $18.44–$20.24, opened at $18.91.
- Volume was 255.00K shares, 0.5x its 50-day average of 558.38K — lighter than usual.
- 52-week range $17.86–$32.00; today's close sits at 15% of that range, 37.4% below the 52-week high.
Oct 8, 2026 — BRVE rises 2.7% to $19.09
- Closed at $19.09, +2.74% vs the prior close of $18.58. Day range $17.86–$19.32, opened at $18.53.
- Volume was 389.20K shares, 0.7x its 50-day average of 562.23K.
- 52-week range $17.86–$32.00; today's close sits at 9% of that range, 40.3% below the 52-week high.
Oct 7, 2026 — BRVE slides 6.1% to $18.58, a 1-month low
- Closed at $18.58, -6.11% vs the prior close of $19.79. Day range $18.47–$19.65, opened at $19.61.
- Volume was 336.90K shares, 0.6x its 50-day average of 567.47K — lighter than usual.
- 52-week range $18.47–$32.00; today's close sits at 1% of that range, 41.9% below the 52-week high.
Oct 6, 2026 — BRVE slides 7.3% to $19.79, a 1-month low
- Closed at $19.79, -7.31% vs the prior close of $21.35. Day range $19.67–$21.59, opened at $21.59.
- Volume was 590.30K shares, 1.0x its 50-day average of 566.92K.
- 52-week range $19.67–$32.00; today's close sits at 1% of that range, 38.2% below the 52-week high.
Oct 5, 2026 — BRVE rises 0.4% to $21.35
- Closed at $21.35, +0.38% vs the prior close of $21.27. Day range $19.83–$22.02, opened at $21.57.
- Volume was 889.00K shares, 1.6x its 50-day average of 559.07K.
- 52-week range $19.83–$32.00; today's close sits at 12% of that range, 33.3% below the 52-week high.
Oct 2, 2026 — BRVE dips 0.7% to $21.27
- Closed at $21.27, -0.65% vs the prior close of $21.41. Day range $20.77–$21.98, opened at $21.44.
- Volume was 462.80K shares, 0.8x its 50-day average of 561.48K.
- 52-week range $19.88–$32.00; today's close sits at 11% of that range, 33.5% below the 52-week high.
BRVE latest news & SEC filings
Every SEC filing by or about BRVE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 10, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 8, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$14.99M (prior year -$381.00K) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$2.51 (prior year -$0.14) (loss widened vs Jun 30, 2025)
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 18, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 14, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Chimovits Erez bought 1,666,667 shares at $18.00 (≈$30.00M) on Aug 7, 2026
- Chimovits Erez bought 273,333 shares at $18.00 (≈$4.92M) on Aug 7, 2026
- Chimovits Erez bought 1,666,667 shares at $18.00 (≈$30.00M) on Aug 7, 2026
- Chimovits Erez bought 273,333 shares at $18.00 (≈$4.92M) on Aug 7, 2026
- Chimovits Erez bought 1,666,667 shares at $18.00 (≈$30.00M) on Aug 7, 2026
- Chimovits Erez bought 273,333 shares at $18.00 (≈$4.92M) on Aug 7, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Orbimed Genesis Gp Llc bought 1,666,667 shares at $18.00 (≈$30.00M) on Aug 7, 2026
- Orbimed Genesis Gp Llc bought 273,333 shares at $18.00 (≈$4.92M) on Aug 7, 2026
- Orbimed Genesis Gp Llc bought 1,666,667 shares at $18.00 (≈$30.00M) on Aug 7, 2026
- Orbimed Genesis Gp Llc bought 273,333 shares at $18.00 (≈$4.92M) on Aug 7, 2026
- Orbimed Capital Gp Ix Llc bought 1,666,667 shares at $18.00 (≈$30.00M) on Aug 7, 2026
- Orbimed Capital Gp Ix Llc bought 273,333 shares at $18.00 (≈$4.92M) on Aug 7, 2026
- …plus 11 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
Aug 6, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 6, 2026 · Form 424B4 — Final prospectus with offering price
Final prospectus with offering price
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade BRVE
- Last results release: Sep 8, 2026 (8-K Item 2.02).
- How much it moves: over the last 20 sessions the average daily move was 5.39% (largest 14.3%). That is a volatile stock.
- Liquidity: about 545.51K shares (≈$10.21M) trade per day on average.
- 52-week position: $18.71 vs a range of $17.86–$32.00 (6% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Erez Chimovits bought 1,666,667 shares on Aug 7, 2026.
- Latest filings: 10-Q Sep 8, 2026; 8-K Sep 8, 2026; 8-K Aug 7, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
BRVE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 19.50 | 19.59 | 18.01 | 18.71 | 414.85K |
| Oct 15, 2026 | 19.54 | 20.13 | 19.18 | 19.55 | 206.10K |
| Oct 14, 2026 | 19.33 | 19.90 | 18.62 | 19.34 | 462.80K |
| Oct 13, 2026 | 20.44 | 20.56 | 19.04 | 19.33 | 212.30K |
| Oct 12, 2026 | 20.17 | 20.78 | 19.22 | 20.36 | 155.10K |
| Oct 9, 2026 | 18.91 | 20.24 | 18.44 | 20.02 | 255.00K |
| Oct 8, 2026 | 18.53 | 19.32 | 17.86 | 19.09 | 389.20K |
| Oct 7, 2026 | 19.61 | 19.65 | 18.47 | 18.58 | 336.90K |
| Oct 6, 2026 | 21.59 | 21.59 | 19.67 | 19.79 | 590.30K |
| Oct 5, 2026 | 21.57 | 22.02 | 19.83 | 21.35 | 889.00K |
| Oct 2, 2026 | 21.44 | 21.98 | 20.77 | 21.27 | 462.80K |
| Oct 1, 2026 | 19.90 | 22.36 | 19.88 | 21.41 | 669.40K |
| Sep 30, 2026 | 22.30 | 22.30 | 20.01 | 20.20 | 967.50K |
| Sep 29, 2026 | 21.00 | 22.51 | 20.37 | 22.34 | 719.20K |
| Sep 28, 2026 | 20.25 | 22.05 | 20.01 | 21.07 | 389.30K |
| Sep 25, 2026 | 23.58 | 23.86 | 20.53 | 20.62 | 471.80K |
| Sep 24, 2026 | 21.41 | 23.80 | 20.70 | 23.37 | 396.70K |
| Sep 23, 2026 | 23.21 | 23.77 | 21.31 | 21.46 | 521.70K |
| Sep 22, 2026 | 25.41 | 25.41 | 23.42 | 23.61 | 829.40K |
| Sep 21, 2026 | 28.90 | 28.90 | 24.63 | 25.02 | 1.57M |
About Braveheart Bio
Braveheart Bio (BRVE) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2131524.
BRVE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Vineeta Agarwala | Director | Aug 14, 2026 |
| Jasper Bos | Director | Aug 7, 2026 |
| Erez Chimovits | Director | Aug 11, 2026 |
| Jason V Coloma | Director | Aug 5, 2026 |
| Tim Lohoff | Director | Aug 7, 2026 |
| David Charles Lubner | Director | Aug 7, 2026 |
| David I Malek | Director | Aug 7, 2026 |
| Travis Murdoch | CEO and President | Aug 7, 2026 |
| Advisors Llc Orbimed | Director | Aug 11, 2026 |
| Capital Gp Ix Llc Orbimed | Director | Aug 11, 2026 |
| Genesis Gp Llc Orbimed | Director | Aug 11, 2026 |
| Christopher Viehbacher | Director | Aug 7, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Michele A. Anderson | Chief Development Officer | Aug 7, 2026 |
| Travis Murdoch | CEO and President | Aug 7, 2026 |
| James Paul Rickey | Chief Financial Officer | Aug 7, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 7, 2026 | Erez Chimovits | Buy | 1,666,667 | $18.00 |
| Aug 7, 2026 | Erez Chimovits | Buy | 273,333 | $18.00 |
| Aug 7, 2026 | Erez Chimovits | Buy | 1,666,667 | $18.00 |
| Aug 7, 2026 | Erez Chimovits | Buy | 273,333 | $18.00 |
| Aug 7, 2026 | Erez Chimovits | Buy | 1,666,667 | $18.00 |
| Aug 7, 2026 | Erez Chimovits | Buy | 273,333 | $18.00 |
| Aug 7, 2026 | Erez Chimovits | Buy | 1,666,667 | $18.00 |
| Aug 7, 2026 | Erez Chimovits | Buy | 273,333 | $18.00 |
| Aug 7, 2026 | Genesis Gp Llc Orbimed | Buy | 1,666,667 | $18.00 |
| Aug 7, 2026 | Genesis Gp Llc Orbimed | Buy | 273,333 | $18.00 |
| Aug 7, 2026 | Genesis Gp Llc Orbimed | Buy | 1,666,667 | $18.00 |
| Aug 7, 2026 | Genesis Gp Llc Orbimed | Buy | 273,333 | $18.00 |
| Aug 7, 2026 | Capital Gp Ix Llc Orbimed | Buy | 1,666,667 | $18.00 |
| Aug 7, 2026 | Capital Gp Ix Llc Orbimed | Buy | 273,333 | $18.00 |
| Aug 7, 2026 | Capital Gp Ix Llc Orbimed | Buy | 1,666,667 | $18.00 |
BRVE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $126.96M, total liabilities $9.34M, cash $122.83M (as of Jun 30, 2026).
BRVE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Sep 8, 2026 | 8-K Item 2.02 (results) | $29.41 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BRVE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.